Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING‐dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer

Although PARP inhibitor (PARPi) has been proven to be a promising anticancer drug in cancer patients harboring BRCA1/2 mutation, it provides limited clinical benefit in colorectal cancer patients with a low prevalence of BRCA1/2 mutations. In our study, we found PARPi talazoparib significantly induc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Liu, Weizhen, Shen, Qian, Tao, Ruikang, Li, Chengguo, Lin, Yao, Huang, Yongzhou, Yang, Lei, Xie, Gengchen, Bai, Jie, Li, Ruidong, Wang, Lulu, Tao, Kaixiong, Yin, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637067/
https://www.ncbi.nlm.nih.gov/pubmed/37702298
http://dx.doi.org/10.1111/cas.15961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637067/
https://www.ncbi.nlm.nih.gov/pubmed/37702298
http://dx.doi.org/10.1111/cas.15961

Ejemplares similares